What is the target hemoglobin range recommended by the KDOQI for patients receiving erythropoiesis-stimulating agents?

The target hemoglobin range recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) for patients receiving erythropoiesis-stimulating agents is 11.0-12.0 g/dL. This range is suggested to help ensure adequate red blood cell production in patients with chronic kidney disease who may be experiencing anemia due to diminished erythropoietin production.

Maintaining hemoglobin levels within this range is vital for reducing the risks of complications associated with low hemoglobin, such as fatigue, decreased quality of life, and potential cardiovascular issues. Ensuring that hemoglobin does not exceed this target is also important because higher hemoglobin levels can increase the risk of adverse cardiovascular outcomes. The guidance provided by KDOQI supports a balanced approach to treatment that aims to alleviate anemia while minimizing potential risks associated with erythropoiesis-stimulating agents.